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The molecular building of protein, DNA, and RNA nanostructures is relevant in many areas 16	
of biological and material sciences. Nanoscale engineering was pioneered with proteins, yet 17	
DNA is rapidly gaining traction. But, what are the advantages of the different biopolymers 18	
and which is best suited for a given molecular structure, function, or application? In this 19	
Review, we evaluate proteins’ and DNA/RNA’s different structural properties, possible 20	
designs and synthetic routes for functional nanostructures. By comparing protein 21	
engineering and DNA nanotechnology, we highlight molecular architectures that are relevant 22	
for applied and fundamental science. 23	
 24	
 25	
Introduction 26	
 27	
Designing and engineering proteins is both scientifically exciting and of practical relevance in 28	
many areas including biotechnology and biomedicine. Protein engineering has provided, for 29	
example, new enzymes for industrial biocatalysis1-4, highly tailored antibodies for cancer 30	
treatment5 easily trackable fluorescent proteins for biological research6,7, and efficient 31	
polymerases for forensic DNA detetection8.  32	
 33	
Molecular construction using DNA is rapidly catching up, as evidenced by DNA aptamers 34	
and rationally designed DNA nanostructures9-18. This use of DNA is surprising as its 35	
biological role lies in encoding genetic information and influencing gene expression. 36	
Nevertheless, nucleic acids have been re-tooled into artificial recognition agents and 37	
structural scaffolds for applications in materials science, biophysical research and 38	
increasingly in synthetic biology. DNA nanotechnology, in particular, has drastically 39	
expanded the repertoire of rationally designed nanostructures beyond RNA and DNA 40	
aptamers that can bind proteins or other ligands19-24. 41	
 42	
With protein engineering and DNA nanotechnology growing rapidly, several fundamental 43	
questions emerge. What are the relative strengths of polypeptides, DNA and RNA in terms 44	
of their structural and functional properties, as well as the ease of engineering? Which 45	
molecular building material is best suited for a given application? Moreover, considering that 46	
synthetic biology and nanobiotechnology are exciting areas, what are the most promising 47	
applications of new bio-nanostructures? Answering these questions is important as protein 48	
engineering and DNA nanotechnology are often seen as separate research areas with 49	
limited interaction.  50	
 51	
In this Review, we synoptically compare protein, DNA and RNA as building materials for 52	
nanostructures with defined architecture and function. By answering the above questions, 53	
the Review aims for a unifying understanding of strengths and weaknesses of these 54	
biopolymers. The survey starts with a side-by-side evaluation of proteins and DNA/RNA in 55	
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terms of their physico-chemical properties, the principles for their rational design and 56	
engineering, and methods for their chemical and biochemical synthesis. The ensuing three 57	
sections compare how these differences influence the functional performance of protein or 58	
DNA nanostructures as biomolecular recognition agents, enzymatic catalysts, and structural 59	
scaffolds. This includes a discussion of applications in biotechnology, biomedicine, synthetic 60	
biology, and materials research. A concluding section outlines possible avenues of future 61	
research. Given the broad scope of the Review, only a selection but not all references of the 62	
field can be cited. The Review is written for a broad and interdisciplinary audience interested 63	
in biomolecular design with chemical precision. 64	
 65	
 66	
 Properties and structures of biopolymers  67	
 68	
Chemical diversity, folding, structural complexity, compactness, and dimensions of proteins 69	
and DNA affect their engineering properties. The 20 different amino acids of proteins lead to 70	
a broad chemical diversity (Figure 1, Box 1) and a larger scope for non-covalent interactions 71	
during folding compared to DNA. H-bonding and non-covalent interactions in the polypeptide 72	
backbone enable many secondary structures and over 1300 known protein folds (Box 1)25. 73	
An undesirable consequence of structural complexity is misfolding and aggregation26. 74	
However, in successful outcomes, a charge-neutral and conformationally flexible backbone 75	
usually yields compact protein architectures of moderate dimensions (< 10 nm, average size 76	
of 34 kD in bacteria and 49 kD in eukaryotes27), which also reflects the small size of amino 77	
acids (Box 1, Figure 1). 78	
 79	
DNA and RNA are each built from four standard nucleotides. Hence, the chemical diversity 80	
and scope for non-covalent interactions in folding of DNA and RNA are more contained 81	
compared to proteins (Figure 1, Box 1). This is exemplarily illustrated by the lack of 82	
positively charged residues and direct ion bridges even though metal cations can lead to 83	
indirect bridges. DNA strands interact primarily through hydrogen bonding between base 84	
pairs and hydrophobic base stacking. The contained scope of interactions leads to fewer 85	
folding arrangements that are possible for proteins (Figure 1, Box 1). This makes DNA 86	
folding easy to predict when Watson-Crick base-paired duplexes (Box 1) are the core 87	
element of the architectures.  Additional Hoogsteen base pairs expand the range of 88	
structures to G-quadruplexes or triplexes (Box 1), and cytosine-cytosine pairs to the i-motif. 89	
Folded DNA structures are usually less compact than proteins partly due to the electrostatic 90	
repulsion of the negatively charged backbone. Furthermore, duplexes with a high 91	
persistence length of around 50 nm28 easily yield up to 100 nm-large DNA nanostructures 92	
which also reflects the bigger size of nucleotides compared to amino acids (Figure 1, Box 1). 93	
 94	
The different characteristics of proteins and DNA influence the engineering of new 95	
architectures, as different engineering approaches need to balance between the strengths 96	
and weaknesses of the biopolymers Due to the chemical diversity and complex folding of 97	
proteins, most engineering approaches rely on the modification of naturally occurring 98	
proteins. Chemical diversity can be controlled by means of rational engineering, which is 99	
used to alter few amino acids or peptide stretches and is often guided by structural insight or 100	
computational tools (Box 2). Compared to rational design, directed evolution explores 101	
greater chemical diversity by creating large gene libraries of randomized sequences, 102	
expressing the corresponding proteins, and screening their properties of interest29-31; 103	
misfolded proteins are discarded in the screen (Box 2). Directed evolution methods mRNA 104	
display32,33 and yeast display cells34-36 are of particular interest. The former achieves a large 105	
chemical diversity by translating proteins and chemically associating them with their 106	
encoding mRNA for screening and identification. By comparison, the former method obtains 107	
proteins with specific biomolecular functions by expressing large amounts of proteins, post-108	
translational modifying them and displaying them on the cell wall of yeast for easy screening. 109	
Computer-aided de novo design explores the largest diversity without requiring biological 110	
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scaffolds as starting point,37-41 even though the design can be inspired by natural templates, 111	
and use existing secondary structure elements42 (Box 2, Figure 1). Given the difficult 112	
prediction of complex folding, mostly small proteins are designed even though higher 113	
computing power will help increase size and complexity38. A powerful strategy is to combine 114	
two or more of the above methods to compensate their isolated drawbacks42-44. 115	
 116	
Engineering with nucleic acids is different as the small chemical diversity can translate into 117	
simple folding. Novel structures of aptamers21,45 are generated via directed evolution method 118	
SELEX (Box 2) that is simpler than analogous protein methods because in nucleic acids 119	
both function and encoding sequence are combined (Box 2). Complementary, completely 120	
rational de novo design10,14,17 can build a nano-sized object of almost any geometry from 121	
scratch because folding relies on simple base-pair rules and a small set of standard 122	
structural building units including DNA duplex units, hairpins, and Holliday junctions (Box 2). 123	
The rationally designed DNA nanostructures are, unlike aptamers, usually composed of 124	
multiple DNA strands and reach sizes up to 100 nm even. Recently, single-chain DNA 125	
origami46 and co-transcriptionally folded single-chain RNA nanostructures have been 126	
prepared47. In addition, microscale symmetric DNA origami assemblies48 and similarly sized 127	
arrays with arbitrary patterns are accessible49. 128	
 129	
 130	
[H1] Designing and building function  131	
 132	
Protein and DNA/RNA differ considerably and this contrast has consequences on the 133	
building of functional nanostructures, which are relevant in biomedicine, biotechnology, 134	
synthetic biology, and material sciences. The following three sections discuss these 135	
differences in light of three representative functions: biomolecular recognition, catalysis, and 136	
structural support. Other functions such as motor activity50-54 or cellular signal processing 137	
and biocomputation11,55,56 are not covered due to space limitations, whereas transmembrane 138	
transport by protein vs. DNA pores57-60 has been compared previously61,62. 139	
 140	
 141	
[H2] Biomolecular recognition  142	
 143	
Biomolecular recognition enables highly specific and tight binding of ligands. Molecular 144	
binding agents are hence of relevance in biosensing and biomedicine, and many research 145	
applications including analysis of biological cells. We evaluate binding agents by comparing 146	
antibodies, antibody derivatives, other protein-based recognition scaffolds to DNA/RNA-147	
based aptamers. The chemical and structural properties of proteins and DNA are key 148	
because specific and tight recognition requires the side chains of the biopolymers to line a 149	
binding pocket that is structurally and chemically complementary to the ligand. Furthermore, 150	
the engineering strategies used for the different biopolymers strongly influence how easily 151	
binding sites are obtained. 152	
 153	
Antibodies and antibody derivatives illustrate that proteins excel on specific and tight 154	
recognition, and suitable strategies to achieve both properties. Antibodies are Y-shaped 155	
structures with two identical arms termed Fab for fragment antigen-binding63,64(Figure 2A); 156	
the bottom stem of the Y-shaped structure — the fragment crystallisable (Fc)-region — does 157	
not interact with antigens, but with other receptors (Figure 2A). Each Fab region is 158	
composed by a pair of two polypeptides— heavy and light chain — whereby the site for 159	
antigen binding is formed by two corresponding antigen-binding loops. Two rather than one 160	
loop better exploit the chemical and structural diversity of the amino acids that is required for 161	
highly specific recognition of ligands.  162	
 163	
The chemical and structural diversity can be harnessed in biotechnology with the mutational 164	
mechanism of antibody-producing immune cells using hybridoma technology. In this method, 165	
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continuously growing hybrid cells each one producing a monoclonal antibody type specific 166	
for one recognition motif65.  The hybrid cells are made from antibody-producing, yet short-167	
lived B immune cells and immortal cancer cells. This approach uses mouse immune cells, 168	
therefore the surface of the mice-derived antibodies causes immunogenicity in humans66-68. 169	
However, antibodies can be humanized by genetically fusing the mice-derived antigen-170	
binding loops into a human antibody framework66-68 thereby expanding their therapeutic 171	
applications. Alternatively, antigen-binding units are sourced from bacterial phage-display 172	
libraries69 or also yeast libraries34,35. Both routes generate gene libraries of randomized 173	
sequences outside cells and then expressing and screening the proteins. The advantage of 174	
using yeast libraries is that antibodies and other mammalian cell-surface and secreted 175	
proteins such as receptors and cytokines are post-translational modified with carbohydrates 176	
in the cell endoplasmic reticulum to achieve efficient folding and activity34,35. 177	
 178	
Antibody engineering also yielded variants with two different Fabs to recognize two distinct 179	
antigens. These bispecific antibodies5,7063,71.  are used in immune cancer therapy to recruit 180	
via specific recognition cytotoxic T cells to the targeted tumour cells; the Fc part can also 181	
help bind another immune cell such as macrophage. Bispecific antibodies are used for other 182	
biomedical applications, such as to co-localize two proteins in cells and test the biological 183	
effect.63. Bispecific antibodies can be produced within a cell line. But this can result in a 184	
uncontrolled combination of the two light and heavy chains present within each cell and 185	
inactive isoforms72. Rational engineering can overcome the problem by heterodimerising the 186	
heavy chains70 even though the pairing with light chains is still uncontrolled. One solution 187	
involves using of a single common light chain5 however a better alternative is to produce in 188	
two separate cells two half antibodies, each composed of the matching heavy and light 189	
chain. After their purification, the matching antibody halves are then specifically coupled by 190	
exploiting the rationally engineered complementary ‘knob-in-hole’ surface structures on the 191	
two heavy chains63. 192	
 193	
The cumbersome fabrication of complete antibodies limits their use for many applications. 194	
Engineering approaches can truncate the Fc region and stabilize the remaining single Fabs 195	
by looping the light and shortened heavy chain into a single polypeptide. Due to the smaller 196	
size, these single-chain variable fragment antibodies can display higher tissue penetration 197	
without compromising affinity73. Their antigen-binding region can also be optimised with 198	
directed evolution using yeast display34,35.The most important biomedical application of 199	
single-chain variable fragments is in cancer therapy (Rosenbaum L. "Tragedy, 200	
Perseverance, and Chance - The Story of CAR-T Therapy". The New England Journal of 201	
Medicine. 2017, 377, 1313–1315). The fragments are parts of chimeric antigen receptors 202	
(CAR) that are engineered onto immunological T-cells to recognise tumour cells. The 203	
chimeric receptors comprise the extracellular recognition domain, a genetically fused 204	
membrane-spanning domain, and an intracellular signalling endodomain (Gross G, Waks T, 205	
Eshhar Z. "Expression of immunoglobulin-T-cell receptor chimeric molecules as functional 206	
receptors with antibody-type specificity". Proceedings of the National Academy of Sciences 207	
of the United States of America. 1989, 86: 10024–8). When CARs on T-cells bind to cognate 208	
surface proteins on tumours, multiple CARs form lateral cluster in the membrane which in 209	
turn leads to signalling and activation and reprogramming of T-cells into cytotoxic cells that 210	
destroy the cancer cells (Rosenbaum L. "Tragedy, Perseverance, and Chance - The Story of 211	
CAR-T Therapy". The New England Journal of Medicine. 2017, 377, 1313–1315). 212	
 213	
An alternative solution to large antibodies are camelid antibodies, as  they naturally lack the 214	
light chain, which is compensated by a slightly longer heavy chain74,75. These compact 215	
binding agents, aptly termed nanobodies76, have high structural stability75,77 and are less 216	
prone to aggregation76. The small units can reach epitopes inaccessible to larger 217	
antibodies78 and can also be expressed in a form that is fused to green fluorescent protein79.  218	
 219	
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Recognition can be engineered into a non-antibody scaffold as shown by designed ankyrin 220	
repeat proteins (DARPins) (Figure 2B) which are derived from the of integral membrane 221	
protein ankyrin80. A DARPIn recognition site is composed of up to five repetitive looped 222	
homologous units and, because of its modular structure, it mimics the modular recognition 223	
principle of ankyrins. The loops are selected by screening a library of around 1000 repeats 224	
of different sequences81. DARPins have been used as crystallization chaperone82 and 225	
sensors of protein conformation, and to induce apoptosis in tumors83. The concept of repeat-226	
based recognition scaffolds is common and has been implemented using sequences with 227	
leucine-rich-repeats84, a 42-residue tetratricopeptide repeat variant85, HEAT-like repeats86, 228	
and others87,88.  229	
 230	
Non-antibody recognition scaffolds smaller than DARPins are peptide macrocycles including 231	
immunosuppressant cyclosporine89. Macrocycles feature around 8-12 amino acids including 232	
D-enantiomers and L-versions with non-standard residues. The recognition spectrum of 233	
macrocyles has been explored by sampling the available structure space by sequence 234	
design and energy landscape calculations90.  235	
 236	
As illustrated above, the chemical variety of polypeptides help create strong and specific 237	
molecular recognition agents. Both biological and in vitro generated libraries can be 238	
screened to identify highly functional binders, while rational engineering helps redesign the 239	
overall scaffold. How do RNA and DNA-based recognition agents compare to the impressive 240	
properties of proteins and peptides? RNA or DNA can form remarkably strong and 241	
specifically binding aptamers (Figure 2C) even though the chemical diversity of endogenous 242	
nucleic acids is lower than for proteins21-24,45. A compensatory factor is the relatively short 243	
length of DNA or DNA-aptamer strands, which makes it easy to explore via SELEX a greater 244	
physicochemical parameter space than would be possible for proteins19,20. Furthermore, 245	
aptamers can address some of the shortcomings of antibodies. For example, the folded 246	
strands are fabricated from commercial chemical synthesis, whereas antibodies require 247	
more complex manufacturing processes that make use of cell-based expression systems 248	
followed by purification to remove biological contaminants. As a drawback, DNA and RNA 249	
make aptamers unstable towards nucleases, which can limit their use in therapeutic 250	
applications. 251	
 252	
Aptamers are used in diagnostics, therapeutics, biosensing and as research tools for cell 253	
biology21-24,45. One clinically approved RNA aptamer is discussed to highlight structural 254	
features as well as strategies to address nuclease instability91. Aptamer Pegaptanib is 255	
approved by the Food and Drug Administration and is used against age-related macular 256	
degeneration. It binds the molecular target vascular endothelial growth factor with an affinity 257	
of around 50 pM91. The RNA strand is 27 nt long and folds into a hairpin structure with an 258	
internal loop, which is bent into the biologically active 3D conformation . To increase 259	
nuclease stability, all of the 13 pyrimidines are 2′-fluorine-modified, while 12 of the 14 260	
purines carry the 2′-O-methy modification. Furthermore, a 40 kDa polyethylene glycol moiety 261	
is linked to the 5′ terminus to sterically screen nucleases. More aptamers are developed for 262	
other diseases23. Aptamers can also be integrated into rationally designed nanostructures to 263	
achieve multiple recognition capabilities92,93.  264	
 265	
Compared to antibodies or related structures, aptamers are less widely used in biomedicine. 266	
This is not due to the insufficiency of nucleic acids to form aptamers with high selectivity and 267	
specificity or to the lack of suitable engineering methods that can harness the chemical and 268	
structural potential. Both proteins and nucleic acid rely on screening methods of randomized 269	
libraries because the engineering of binding sites is harder with rational design. The higher 270	
use of protein-based recognition agents in therapeutics is mostly due to the lower nuclease 271	
stability of DNA or RNA aptamers, and filtration by the renal system21. 272	
 273	
 274	
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[H2] Biocatalysis  275	
 276	
Biocatalysis is essential in industrial biotechnology. It helps to synthesize chemicals and 277	
pharmaceuticals2,94-96, biofuels97,98, foodstuff including proteins, but also in biomedicine and 278	
biosensing3. It furthermore provides an environmentally friendly and cost effective alternative 279	
to classical transition metal catalysts99. Biocatalysis is enabled by enzymes, but can 280	
additionally be mediated by RNAzymes or DNAzymes.  281	
 282	
Efficient catalysts accelerate chemical reactions and control which part of the substrate 283	
undergoes a specific chemical transformation. The biopolymer residues are key in both 284	
cases because fast catalysis requires the active site to weakly bind the substrate but 285	
energetically stabilize the reaction transition state. Furthermore, residues achieve chemical 286	
selectivity by recognising the substrate. Industrial applications requires biocatalysts that 287	
exhibit affinity for a defined range of substrates 97,100,  increased rate and yield for the 288	
chemical transformations, a high stereo-, chemo- and/or regioselectivity99, or tolerance for 289	
extreme conditions including elevated or lower temperature, organic solvents, and/or 290	
inhibitory chemicals4. Enzymes are outstanding biocatalysts as they meet these 291	
requirements. With their diverse repertoire of amino acids (various sizes, polarity or charge), 292	
active sites are formed to specifically interact with substrates and transitions states2,4,101. 293	
Several engineering approaches can harness the advantages of proteins and turn them into 294	
valuable tools for industrial processes. For example, traditional rational design102 on a 295	
nitrilase with a single amino acid replacement increased the enantioselectivity by 11% to 296	
98.5% for the R-isomer of a precursor for a cholesterol-lowering drug103.  297	
 298	
Directed evolution with libraries exploits a wider chemical and structural repertoire than 299	
rational design29,30. Means to diversify the library are gene shuffling where a gene is 300	
randomly fragmented and the fragments are then homologously recombined back into a 301	
more diverse set of genes via polymerase chain reaction (PCR) reassembly104 but also 302	
cassette mutagenesis to replace a small subset of a gene with synthetic DNA of randomized 303	
sequence105,106, and error-prone PCR. Directed evolution helped to turn iron-haem 304	
containing cytochrome P450 into a biocatalyst for the highly enantioselective amination of 305	
benzylic C-H bonds107, thereby addressing a demand for an efficient and renewable catalyst 306	
for this reaction. The cytochrome was also engineered to perform the industrially important 307	
anti-Markovnikov oxidation of styrenes with high efficiency108.  308	
 309	
The extent of structural re-arrangement afforded by directed evolution is illustrated by a 310	
retro-aldolase. In this case, the reactive lysine in the original active sites is replaced by a 311	
lysine in a new substrate-binding pocket109 (Figure 3A). In a more drastic case, a non-312	
catalytic scaffold was converted into an RNA ligase32 through a complete remodelling of the 313	
active site110, including enhanced conformational dynamics110,111. This drastic change is 314	
likely caused by the in vitro production of the protein library, which does not impose any of 315	
the constraints observed in cell-based expression. Indeed, the evolution of a 316	
metalloenzymes for olefin metathesis via bacterial protein production needed the screened 317	
enzymes to be located in the bacterial periplasm to avoid metalloenzyme-inhibiting 318	
glutathione in the cytoplasm1. Similarly, enzymes can also be generated with yeast to 319	
display the screened proteins on the cell surface36,112. 320	
 321	
To allow for more directed changes in enzyme structure and function, evolution and 322	
screening can be conducted with targeted libraries,29,30 which involves combining mutations 323	
from different rational design variants with rounds of error-prone PCR113, or sequencing 324	
library hits to identify gene segments to be genetically randomized96, or guiding the creation 325	
of randomised libraries with computational design114-116. For example, focused mutagenesis 326	
resulted in polysialyltransferase enzymes to produce polysaccharides with narrow size 327	
distribution ideal for glycoengineering applications117. Computations also enabled the re-328	
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design of the active site of an amine transaminase to attain marginal activity for the 329	
synthesis of the chiral amine precursor for antidiabetic drug sitagliptin; directed evolution 330	
followed to optimize the enzyme to the manufacturing settings99. In another case, 331	
computational approaches were used to develop a statistical model to establish the 332	
relationships between catalytic activity and the structures of interacting small-molecule and 333	
protein. This resulted in targeted libraries as demonstrated for a halohydrin dehalogenase to 334	
synthesize a precursor for a cholesterol-lowering drug118. Hydrolytic enzymes comprising  a 335	
catalytic triade of cysteine-histidine-glutamic acid placed inside a bundle of seven peptide α-336	
helices (Figure 3C) have been designed using solely computational approaches119.  337	
 338	
The production of Kemp eliminase illustrates the benefit of combining all previous 339	
engineering routes. Kemp eliminase was  computationally designed, then  subjected to in 340	
vitro evolution114, which was followed  by sequencing to identify gene hot spots of high 341	
enzymatic activity, and constructing small focused libraries resulting in a striking overall 342	
6 × 108-fold rate increase (Figure 3B)120.  343	
 344	
Beyond isolated enzymes there is considerable interest to engineer multi-enzyme 345	
assemblies or biocatalytic pathways in which cascades of several enzymes  catalyze 346	
interconnected reactions121. Sophisticated cascades can be obtained by exploiting the 347	
increase by several orders of the catalytic rates due to proximity and/or nanoconfinement of 348	
enzymes 122,123. Other systems that are appealing for industrial use integrate engineered 349	
membrane transporters for whole-cell catalysis in order to efficiently transport both 350	
substrates and products across the cellular barrier124. 351	
 352	
Similar to proteins, DNAzymes and RNAzymes are obtained via the directed evolution 353	
approach. They can catalyse reactions on the cleavage and ligation of the nucleic acid 354	
backbone, photorepair of DNA, and modification of peptides and small molecules125,126. One 355	
exemplary DNAzyme is a RNA-ligase of known X-ray structure (Figure 3D)126. The active 356	
site and the substrate form a compact folding unit that is stabilized by numerous tertiary 357	
interactions. The regioselectivity of the reaction could additionally be elucidated by structure-358	
guided mutagenesis, which also helped to manipulate substrate recognition and reaction 359	
rate. Similarly relevant are RNA polymerase127 and reverse transcriptase ribozymes128. 360	
 361	
The absence of DNA or RNAzymes in industrial applications is surprising as the 362	
biotechnologically relevant production of antibodies and enzyme uses ribosomes, which are 363	
RNAzymes129,130. However, ribosomes are composed by multiple RNA strands and 364	
additional polypeptides (Figure 6A). Such a complex multimeric structure does not easily 365	
lend itself to drastic re-engineering or partial de novo design.  366	
 367	
Catalysts made just of RNA or DNA usually carry-out nucleic acids-related reactions, as 368	
pointed out above, even though directed evolution achieves also non-RNA/RNA 369	
transformations131. Furthermore, compared to proteins, most DNAzymes and RNAzymes 370	
only modestly speed up reactions. The narrower catalytic scope and slow speed is a 371	
consequence of the smaller chemical parameter space of nucleotides than that of amino 372	
acids. Furthermore, the larger size of the nucleotides and the negatively charged DNA 373	
backbone can reduce the structural flexibility and electrostatic tuneability, which is required 374	
for versatile catalysis. Several of these points are being addressed with non-biological xeno 375	
nucleic acids, which allow for a greater chemical diversity than it would be case with native 376	
nuclei acids (Box 2)132-134. An alternative route uses DNA-based hybrid catalysis, where a 377	
transition metal complex is covalently or supramolecularly bound to a duplex. The chiral 378	
microenvironment of DNA in addition to further interactions enable high enantioselectivities 379	
and, often, additional rate accelerations135,136. This idea may in future be extended to 380	
organo-catalysis. In a separate approach, DNA can be used to spatially pre-assemble 381	
organic reagents to facilitate their proximity-induced covalent linkage. In this DNA-templated 382	
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synthesis, short DNA strands -“codons”- are linked to the organic building blocks and 383	
sequence-specifically hybridize to the DNA template which then links the blocks into 384	
oligomers, as demonstrated by the synthesis of a macrocycle137. By bringing together 385	
reagents, DNA only fulfils one function of a catalyst but it does not stabilize the transition 386	
state. DNA-templated synthesis has been developed into a tool in materials discovery138 and 387	
can also be conducted with a DNA-based molecular machinery that controls and records the 388	
formation of covalent bonds139. 389	
 390	
 391	
[H2] Structural support and scaffold 392	
 393	
Structural support is the third function of protein or DNA/RNA nanostructures. In biology, 394	
protein-based cytoskeletal supports define the shape of membranes, organelles, and cells, 395	
but also guide the arrange non-membrane components, such as chromosomes, at defined 396	
position at length scales of up to a few micrometres. Biological structural supports comprise 397	
up to thousands of subunits, in contrast to the monomeric or oligomeric nature of enzymes 398	
or antibodies. As other difference, the function of scaffold proteins relies largely on their 399	
nanoscale morphology and dimensions; catalysis is usually not involved. As similarity, 400	
interactions with other subunits require a fine-grained protein surface, which is the same for 401	
molecular recognition agents.  402	
 403	
In this section, we first describe representative biological protein-based structural scaffolds. 404	
This is necessary as their functions are quite diverse. Then, we discuss new designed 405	
protein assemblies, and their applications. To further appreciate the influence of the building 406	
material, we finally describe DNA-based synthetic scaffolds along with their applications. 407	
 408	
 409	
[H3] Natural protein assemblies 410	
 411	
Biological protein-based scaffolds can be categorized according to their ultrastructural 412	
shape, which is related to their biomolecular functions and molecular architecture of the 413	
subunits. The shapes are fibres, sheets, or hollow shells.  414	
 415	
Microscale rod-like and cylinder-like assemblies physically connect other cellular 416	
components and form the intracellular cytoskeleton (microtubule, intermediate filaments), the 417	
extracellular matrix, and bacterial pili that form hair-like appendages on the cell surface to 418	
form contact to other bacteria and can be involved in biofilm formation140. Rods and cylinders 419	
are also used for intra and intercellular transport such as actin tracks to move cargo with 420	
myosin and other molecular motors or as rotary hooks for propulsion140. 421	
 422	
Sheet-like assemblies are found in bacterial S-layers (Figure 4A), that function as sole 423	
structural exoskeleton for almost all archaea and in eubacteria as attachment matrix for exo-424	
enzymes or to invade host cells, such as for Bacillus anthracis layers141-143. The SbsB 425	
protein lattice from a Gram-positive bacterium illustrates this molecular architecture (Figure 426	
4A)144. The protein consists of an amino-terminal cell-wall attachment domain and six 427	
consecutive immunoglobulin-like domains. The latter domains arrange in a crystallization 428	
unit that is stabilized by interdomain Ca2+ coordination with histidine and other metal-429	
chelating amino acids. This compact unit pre-positions the areas of intermolecular contact to 430	
facilitate lateral assembly into the protein lattice. 431	
 432	
Hollow protein shells such as viral capsids define the shape of viral particles, protect the 433	
enclosed viral genetic material, and facilitate cell surface recognition by host membranes 434	
through the display of recognition motifs145. Typical viral shells have an icosahedral or rod 435	
ultrastructure such as the M13 bacteriophage (Figure 4B). The approximately 50 nm-wide 436	
and up to a micrometre-long shell is mostly assembled from the major p8 coat protein. p8 437	
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interacts via its inner-facing, positively charged side with the single-stranded circular viral 438	
DNA. Each two other proteins form the caps of the filament. A related class of protein shells 439	
are bacterial micro-compartments. These organelles contain different enzymes to initiate 440	
catalytic cascades to, for example, fix CO2 or oxidise carbon sources for energy 441	
release146,147. The icosahedric compartment shell usually comprises at least two different 442	
protein types. The first forms pentamers positioned at the vertices of the icosahedral shell. 443	
The second assembles into cyclic hexagons that constitute the shell’s facets147. The 444	
hexagonal circular units enclose a central pore, which is assumed to facilitate cross-445	
boundary exchange of enzymatic substrate and products. The larger enzymes are retained 446	
inside the bacterial micro-compartment147-149.  447	
 448	
Another protein cage, which can adopt icosahedric symmetry is formed by clathrin. This 449	
protein covers cell membranes via a lattice can shape the membranes into drop-like 450	
intracellular vesicles to transport enclosed molecular cargo into and out of the cells150. The 451	
curved lattice is formed by triskelions in which three protrusions are linked with some 452	
structural flexibility to the central trimerisation domain. Due to the flexibility, interaction 453	
between the three protrusions can form hexamer as well as pentamer units, yielding lattices 454	
with varying numbers of triskelions and symmetries including icosahedrons. A different and 455	
smaller protein shell is ferritin. It is composed of 24 α-helical polypeptides and binds iron 456	
inside cells, yet it does not adhere to membranes. BAR domains that are found in all 457	
eukaryotes, by comparison, form crescent-shaped dimers that binds preferentially to highly 458	
curved negatively charged membranes151 and thereby shape the morphology of the bilayer 459	
(Figure 4C) and facilitate the clathrin-independent formation of vesicle pits152. 460	
 461	
 462	
[H3] Engineered protein assemblies 463	
 464	
Which type of protein scaffold can be synthetically produced? Rational design helped build 465	
fibres using β-strand peptides that assemble into β-sheets. Alternatively, amphipathic α-466	
helices were designed to interact via coiled-coils to bundle into long fibres153. If the peptides 467	
are straight and short, it is possible to elongate the fibres without branching for up to 468	
hundreds of µm153. Supplementing additional peptides containing flexibly linked α-helices 469	
produced kinked, waved and branched fibres154. Furthermore, pre-assembled blunt-ended 470	
coiled-coil barrels with central channels were used as building blocks to form peptide 471	
nanotubes155,156.  472	
 473	
2D nanosheets could be assembled from an α-helical amphiphilic peptide. Its 3-fold screw 474	
symmetry led to hexagonal packing of helices157. The design of larger 2D protein lattices had 475	
to cope with subunit interfaces that are more corrugated than that of small peptide subunits. 476	
To overcome the limitation, longer ranging metal coordination bonds were installed at the 477	
protein interface via suitable electron-donors histidine and glutamic acid158. The resulting 478	
monomeric proteins assembled into planar arrays up to the micrometre scale upon addition 479	
of Zn2+ that formed metal coordination bonds with the amino acids to bridge the subunits. 2D 480	
protein arrays were also formed via covalent disulphide bonds between protein subunits that 481	
had an inherent C4 symmetry and assembled into a square lattice159.  482	
 483	
By contrast,  a 3D structure was attained without cofactors by using a single-chain α-helical 484	
polypeptide that folded via coiled-coils into the final tetrahedron-shaped product160. In the 485	
alternative and more frequently used multimeric mode, protein cages are assembled from 486	
subunit -proteins that are genetically coupled from distinct oligomeric protein domains in 487	
defined geometric orientation161. For example, a cube-shaped cage of 22 nm side length 488	
was formed by having a trimer at the corners of the cube, a dimer at its edges, and linking 489	
the trimer and the dimer with a semi-rigid α-helical linker (Figure 4D)162. Alternatively, the 490	
linkage could be promoted by non-covalent protein interactions163. In this case, 491	
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complementary packing arrangements are first identified by means of computational 492	
simulations, that are followed by the design of low-energy interfaces between the building 493	
blocks,164 often involving only a few amino acid alterations164,165. The approach facilitaed the 494	
fabrication of produce a 24-subunit, 13-nm diameter octahedron from a trimeric protein 495	
building block163. Even larger compartments were obtained with heterodimeric and 496	
homotrimeric coiled-coil peptide bundles that formed hexagonal networks, which closed into 497	
spherical cages of approximately 100 nm diameter166. 498	
 499	
 500	
[H3] Applications of protein assemblies 501	
 502	
The spherical and multimeric nature of spherical protein assemblies can be exploited in 503	
biomedicine to display peptide epitopes for vaccines. The display of the antigen parts helps 504	
recognition by the immune system and was achieved by genetically linking the 505	
haemagglutinin protein to the ferritin subunits. Immunization with the resulting particles 506	
resulted in antibody titres tenfold higher than those from a reference vaccines167, also 507	
because multiple copies of the epitope were on the vaccine. A related genetic fusion 508	
approach placed poliovirus neutralization epitopes onto nanoparticles formed by the 509	
hepatitis B surface antigen protein168.  510	
 511	
The high lateral density of planar S-layer protein lattices finds applications in biotechnology 512	
as immobilization matrix for metabolic enzymes. The resulting catalytic lattice displayed a 513	
longer shelf-life than the free enzyme169, most likely due to the conformational stabilization 514	
by the lattice170. In a similar fashion, the protein shells of bacterial microcompartments have 515	
been exploited as high-density anchoring site for new enzymes171. 516	
 517	
Examples of applications of synthetic protein scaffolds in synthetic biology includes the 518	
fabrication of a virus-like protein assembly to encapsulate RNA genomes43. The capsid 519	
proteins were first computationally designed into icosahedral assemblies with positively 520	
charged inner surfaces to package full-length mRNA genomes. Then, directed evolution of 521	
capsid proteins led to a 100-fold increased genome packaging, close to reference standard 522	
of a recombinant adeno-associated virus. Existing virion particles that protect DNA were 523	
previously engineered as vectors for clinical gene therapy172. 524	
 525	
Natural and engineered protein assemblies can be also exploited for researching new 526	
materials. The regularity of the protein lattices can be used to spatially organize inorganic 527	
materials, such as nanocrystals with optical, electronic and magnetic properties for 528	
information technology. S-layers, for example, were used to nucleate in situ arrays of 5 nm-529	
sized CdS nanocrystals within the pores of the lattice173. Different approaches have been 530	
explored to direct immobilize arrays of preformed nanoparticles174,175. 531	
 532	
Protein assemblies have further been employed to produce arrays of two different types of 533	
non-biological units, as shown by the engineered M13 phage into hybrid materials for 534	
bioenergy applications176,177. In one study, elongated virus capsids were used to mimic the 535	
photosynthetic light-driven oxidation of water. Porphyrin photosensitizers and catalytic 536	
reaction centres were chemically linked to the p8 coat proteins of the viruses. Immobilization 537	
at tuneable nanoscale spacing on the protein lattice was essential to improve the overall 538	
catalytic activity176. In a second study, the phage formed nanostructured electrodes for Li ion 539	
batteries. To interface with Li, amorphous FePO4 nanoparticles were grown on the p8 coat 540	
protein that had been equipped with a particle-seeding glutamic acid tag. Further electrical 541	
conduction was introduced by placing at the virus cap peptides that exhibited affinity for 542	
single-walled carbon nanotubes. Combining the capsid with nanotubes resulted in a high-543	
density network where electrochemically active nanoparticles were conductively connected 544	
through the carbon nanotubes to the metallic electrode base177. 545	
 546	
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The above studies illustrate the strengths and limitations of large protein assemblies. Protein 547	
self-assembly only requires one to a few types of easily produced protein subunits, which 548	
give rise to larger-order repetitive structures. The regularity is a logical consequence of the 549	
small size of proteins and the short persistence length of polypeptides. Nevertheless, 550	
repetition can be a limitation when more complex ultrastructures are required. Biology 551	
features less symmetric multicomponent complexes such as in transport178 and energy 552	
conversion, but their engineering is difficult. Hence, there is currently no protocol to obtain 553	
protein assemblies of any geometrical shape or any dimension from 20 to 100 nm.  554	
 555	
 556	
[H3] DNA-based scaffolds 557	
 558	
DNA is an alternative building material that can address some limitations of proteins. One 559	
noted advantage of DNA duplexes is their high persistence length, which makes  production 560	
of large non-repetitive nanostructures easier. In addition, the rational  design of DNA 561	
structures is greatly facilitated by the simple base-pairing rules and the predictable folding of 562	
DNA strands. Consequently, DNA nanotechnology relies on building de novo architectures 563	
with simple structural motifs such as DNA duplexes, DNA hairpins and Holliday junction-564	
based cross-overs (Figure 5A) as well as motifs with non-Watson Crick base pairs. DNA 565	
nanotechnology also exploits the relative easy predictions of which interconnected units fold 566	
from a strand with controllable sequence. 567	
 568	
A range of rational design and assembly strategies have been developed for de novo DNA 569	
nanostructures (Box 1). Several representative structures are described here to illustrate the 570	
scope of DNA nanotechnology. All structures are preceded by the tile-based design, in 571	
which short DNA strands assemble into repetitive arrays179-182. 572	
 573	
DNA assemblies into highly tuneable shapes and dimensions are obtained with the origami 574	
approach. A set of single stranded DNA oligonucleotides act as staples to direct the folding 575	
of a long ssDNA scaffold into a nanostructure of non-repetitive architecture10. The scaffolds 576	
are around 10,000 nucleotides long and can lead to nanostructures up to 100 nm. The 577	
structure composed of a layer of parallel aligned duplexes are held together by multiple 578	
cross-overs (Figure 5). Shapes accessible via the design route are rectangles, stars, and a 579	
smiley face (Figure 5A). A box composed of multiple side-ways interconnected origami walls 580	
was also made (Figure 5B)183. Its lid could be opened after adding a key oligonucleotide to 581	
unlocked the duplex-based closure mechanism. 582	
 583	
The DNA origami approach can be extended to yield structures multiple duplex layers 584	
thick184,185. The parallel aligned duplexes can be arranged in square or honeycomb lattices.  585	
caDNAno software greatly facilitates the design of DNA origami structures186. The user 586	
inputs the desired geometry and dimensions of the nanostructure and caDNAno calculates 587	
the sequences of staple strands. However, user experience is required to reposition Holliday 588	
junctions to generate robust and stable constructs. Advances in software development have 589	
further automated the design process to minimize user adjustments187,188. In addition, the 590	
need for staple strands has recently been relieved with the new concept of single-strand 591	
DNA origami, in which a single long nucleic acid strand threads through the nanostructure46 592	
similar to co-transcriptional folding of a single stranded RNA into the final product47. 593	
 594	
A greater range of morphologies is accessible with curved DNA. In contrast to classical DNA 595	
origami with straight helixes, twisted or bent building units can be obtained by inserting or 596	
deleting bases within duplexes189,190. Bundles of neighbouring DNA duplexes can have the 597	
same curvature, and nanostructures resembling twisted ribbons or triangles have been 598	
attained using this kind of DNA duplexes189. Alternatively, DNA origamis can exhibit different 599	
curvatures in neighbouring duplexes that lead to variable distances between cross-overs190. 600	
This curved design approach can be used to form shapes that resemble Genie bottles190 but 601	
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also arrays of clathrin-triskelion-like stars that assembled into a planar higher-order lattice on 602	
supported semifluid bilayer membranes (Figure 5C)191.  603	
 604	
Another route to obtain larger non-repetitive assemblies relies on 3D shape 605	
complementarity192. Here, DNA origamis are designed to assemble into even larger units 606	
than those obtained in standard DNA origami approaches by virtue of duplex protrusions 607	
that exhibit complementary shapes. The complementary units are stabilized by hydrophobic 608	
base-stacking between the corresponding duplexes, rather than direct base-pairing. 609	
Possible resulting structures include synthetic filaments composed of Lego-like bricks and 610	
nanostructures resembling the human body, which comprise three parts:  the legs and two 611	
body halves with hands (Figure 5D). The idea of using blunt-end stacking to arrange large 612	
units has also been demonstrated with orthogonal DNA origami tiles. To achieve 613	
programmable assembly, the planar tiles are designed to feature complementary edges 614	
composed of alternating protruding blunt-ends forming duplex loops and inactive patches193. 615	
 616	
In DNA wireframes, straight duplex modules are connected at tuneable angles into a 617	
network allowing to form regular geometries such as tetrahedrons194 or octahedrons195 or 618	
more  exotic architectures such as nanoscale rabbits, bottles, or spirals wireframes187,196. 619	
The creation of regular or irregular shapes can be guided depending on the use of solely 620	
short DNA oligonucleotides194  or also a DNA scaffold that threads through the 621	
structure187,195,196.  622	
 623	
In brick-design197,198 short oligonucleotides ‘DNA bricks’ assemble into 3D structures 624	
whereby design units are cubes, which include an 8 bp interaction between neighbouring 625	
strands. This design helped create a complete alphabet at the nanoscale. 626	
 627	
 628	
[H3] Applications of DNA-based scaffolds 629	
 630	
One application of rationally designed DNA lies in synthetic biology, in which it is used to 631	
mimic the function of proteinaceous cytoskeletons that shape lipid bilayers199-201. DNA 632	
scaffolds offer more extensive control over morphology and size of the membrane supports 633	
compared to protein structural supports. Membrane anchoring is achieved by attaching tags 634	
such as cholesterol202,203 as observed in the case of flat nanobarges191,204-206 and origami 635	
bricks that can also deform vesicle bilayers207. A related study has showed, however, that 636	
hydrophobic tags attached to cuboid DNA cages interact themselves without membranes. 637	
The cages form defined, quantized oligomers such as dimer, trimer or tetramer that are 638	
stabilized by the hydrophobic interactions208.  639	
 640	
DNA nanostructures can be used to modulate the shape of the lipid bilayers. For example, 641	
simple DNA rings with a size of up to 200 nm were built to control the diameter of spherical 642	
bilayer vesicles formed within the ring209,210. The DNA templates helped to homogenize the 643	
size of conventional vesicles. Unconstrained vesicles are heterogeneous in size and this can 644	
be an issue for biophysical research, but also for the use of cargo-loaded vesicles in 645	
bioimaging and biomedicine. In a different route, a spherical nanoscaffold was coated with a 646	
bilayer membrane to generate a virus-like particle211. With further development, the 647	
approach could prolong the half-life of vesicle-coated drugs. 648	
 649	
Membrane morphologies including tubes, rings, spirals, and organelle-like vesicle arrays 650	
were made with a modular DNA design199. An example of possible DNA scaffold was 651	
assembled from multiple interconnected cylinder-like nanocages, each composed of two 652	
open DNA squares and four connecting pillars (Figure 5E). The presence of lipid anchors 653	
inside the cages enable liposomes to assemble in this confined space. By shortening the 654	
pillars, the vesicles were brought together and fused into elongated membrane tubes. 655	
Asymmetric shortening formed wedge-like cages that produced nanoscale doughnuts and 656	
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similarly shaped membrane rings (Figure 5E). In a related approach, BAR-like  DNA origami 657	
rods with different degrees of curvature were shown to induce membrane bending and 658	
deformation of vesicle on the micrometre-scale201. When added in excess, the curved DNA 659	
rods wrapped around closely, stabilizing the lipid nanotubes201. The membrane vesicles with 660	
controlled dimension and geometry could help understanding the relation between the 661	
morphology of membranes, its lipid composition and dynamics. A related topic of interest is 662	
how the curvature of the membrane alters the activity of membrane proteins within the 663	
photosynthetic or oxidative respiration systems212.  664	
 665	
DNA origami also helped pioneering a new fluorescence microscopic imaging method that 666	
reaches high spatial resolution213. Classical high-resolution methods can suffer from the 667	
short life-time of the fluorophores and insufficient localization. By attaching a single-stranded 668	
DNA tag to the molecule of interest, multiple transient binding of complementary 669	
oligonucleotides with fluorescent labels could enhance the overall signal strength and 670	
improve resolution. The method was pioneered with a DNA origami plate featuring multiple 671	
DNA extensions for hybridization213. It can also help to structurally characterize 3D DNA 672	
polyhedra in solution214. 673	
 674	
In another cell biological application, DNA nanostructures have been designed to probe 675	
changes in intracellular pH. The sensor featured an i-quadruplex section, which switches 676	
between an open and closed state, depending on the pH. The fluorescent emission of a a 677	
fluorophore pair placed on the i-quadruplex provides information of pH changes between 5.8 678	
and 7. The DNA nanostructure helped mapping the pH of early endosomes and the trans-679	
Golgi network in real time215,216. 680	
 681	
DNA nanostructures can also be used in the field of material sciences as templates to guide 682	
the assembly of individual polymers in designed patterns. This approach has facilitated the 683	
study of the properties of single polymer strands useful to generate molecular-scale 684	
electronic devices or optical wires217. DNA nanostructure can also act as scaffold to spatially 685	
control assembly of nanoparticles14. Nanoparticles with plasmonic properties are of 686	
particular interest due to the possible applications in optical218, electronic219 or photonic 687	
devices219,220. As the collective properties are affected by the particle distance and 688	
arrangement14,220, DNA strands has been used as spacer to control the lattice periodicity and 689	
symmetry of nanoparticle assemblies221,222. 690	
 691	
DNA origami can help attain more complex arrangements of nanoparticles than accessible 692	
with DNA strands. For example, a 2D DNA array was used to assemble a chess-board 693	
pattern of alternating 5 nm and 10 nm gold nanoparticles223. Strand displacement allowed 694	
switching of particles and changes in the geometry of the structures224. For more complex 695	
3D patterning, nanoparticles were organized in a regular pattern around DNA nanotubes225 696	
and in a helical arrangement around nanorods226. The precise position of the particles is 697	
reflected in the circular dichroism spectrum. DNA origami nanoantennas were also built to 698	
enhance the fluorescence intensity dyes. A dye molecule was placed in a plasmonic hotspot 699	
of zeptolitre volume between two 100 nm gold nanoparticles and showed a 117-fold 700	
increase of the fluorescence227.  701	
 702	
DNA origami has also been used as a mould to create nanoparticles with predesigned 3D 703	
shapes and surface modifications228. Stiff DNA origami structures were designed and the 704	
scaffold was used to enclose a small gold cluster, which was then grown into a nanoparticle 705	
that assumed the shape of the container. Cuboid, triangular and nanoparticles of more 706	
complex geometries were generated with this approach. The moulding strategy can be 707	
extended to grow polymers inside of the DNA cage229. The remaining DNA strands on the 708	
exterior lead to programmable polymer assembly. DNA cages can also be used to print DNA 709	
sequences onto gold particles230.  710	
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 711	
DNA origami has furthermore guided the production of 3D plasmonic crystals by enclosing 712	
gold nanoparticles inside DNA origami tetrahedra, which were then linked to a diamond 713	
superlattice231. The placement strategy has been adapted to couple molecular emitters to 714	
optically resonating photonic crystal cavities. This approach was based on the predictable 715	
binding of DNA origami onto nanopatterned surfaces with cavities 232,233. DNA scaffolds 716	
modified with different numbers of dyes were positioned onto the photonic crystal cavities. 717	
The tuning of the light intensity by each resonating cavity resulted in the nanoscale 718	
reproduction “The starry night” painting by Van Gogh234. 719	
 720	
 721	
Conclusions and outlook 722	
 723	
This Review has raised and addressed a simple question: how do the different chemical 724	
properties of proteins and DNA/RNA influence the engineering of nanostructures and their 725	
functions? To answer the question, the two building materials were compared in terms of 726	
biochemical properties and ease of engineering. These two aspects have been compared by 727	
looking at two main features of the biopolymers: chemical and structural diversity, and 728	
predictable easy folding. Although both features are desirable, they are not always exhibited 729	
by a single biopolymer type. Proteins are chemically and structurally diverse but this 730	
inherently makes rational design challenging. By comparison, DNA is less diverse but stands 731	
out because of its programmable folding into the predictable nanostructures. This is a 732	
general comparison, as highly functional structures can also be obtained by means of 733	
advanced directed evolution methods.  734	
 735	
The biopolymers have been evaluated for three exemplary functions. In the case of 736	
biomolecular recognition, both proteins and nucleic acids achieve strong and specific 737	
binding. This is easy to understand for proteins due their great chemical parameter space. 738	
For nucleic acids, the limited chemical diversity is compensated by rich directed evolution 739	
libraries. Biocatalysis in industry is dominated by enzymes due to their larger chemical and 740	
structural diversity, and fast catalytic speed; directed evolution is the central approach even 741	
though computational design gains traction. Finally, the building of structural supports can 742	
be achieved with proteins but more easily with DNA nanostructures that often outperform 743	
proteins in several applications. For both protein and DNA-based structural supports, 744	
rational design with computational tools is the principal approach in use thus far. 745	
 746	
What are areas of growth and possible future trends of research? Within protein 747	
engineering, the ever-increasing computational power will facilitate de novo design of 748	
proteins by better predicting polypeptide folding38. In addition, combining rational design with 749	
directed evolution will gain popularity given the considerable benefits. The advantages of 750	
this combined approach have been highlighted by the fabrication of artificial proto-viruses 751	
and efficient enzymes whose essential protein scaffolds were computationally designed but 752	
then functionally optimized via directed evolution43,90.  753	
 754	
Another area of interest are protein hybrids that integrate two functions such as structural 755	
support and catalysis. Inspirational templates are bacterial microcompartments, where 756	
protein scaffolds spatially confine enzymes to accelerate chemical transformations due to 757	
the reduced diffusion distances146-149. Synthetic analogues are intracellular filaments made 758	
from assembled bacterial microcompartment shell protein engineered to capture 759	
enzymes235. Furthermore, the biocatalytically important stoichiometry of enzyme 760	
components within a pathway could be controlled by using an scaffold that was engineered 761	
with interaction domains to specifically recruit the enzymes fused to cognate peptide 762	
ligands236. In both cases, enzyme confinement led to an overall increased catalytic activity 763	
compared to isolated enzymes. Future research on metabolite membrane transporters could 764	
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help organize more enzyme pathways to improve metabolic flux for industrially relevant 765	
chemical synthesis. 766	
 767	
The functionality of proteins can also be enhanced with non-natural amino acids that are 768	
introduced via peptide synthesis237,238, a reprogrammed genetic code239 or by post-synthesis 769	
chemical modifications240. Such chemically precision can turn proteins into tools to probe, 770	
image and control protein function, or provide valuable protein therapeutics239,240. The benefit 771	
of chemical coupling small molecules is illustrated by therapeutically potent antibody-drug 772	
conjugates241. The conjugates specifically recognize cancer cells and simultaneously deliver 773	
their cytotoxic drug payloads. A considerable research interest is to improve the conjugate 774	
quality by avoiding the semi-random coupling of the drugs with the lysine residues at the 775	
sensitive antigen binding sites242. Current research hence aims to develop and apply site-776	
selective reactions that link drugs at defined positions including the antibody disulphides 777	
bonds243. 778	
 779	
Advances in aptamer and DNA nanotechnology have achieved remarkable results. To 780	
further exploit their potential, the limited chemical variety could be addressed by using 781	
chemically modified nucleic acids244 that can improve, for example, molecular recognition of 782	
aptamers133. Furthermore, the scalable and inexpensive production of DNA origami is of 783	
relevance to open up applications in biomedicine and therapy. For classical DNA origami, 784	
staple strands are chemically synthesized at low-scale, whereas scaffolds strands are 785	
sourced from cells. Using a new approach, staples can be made within bacterial hosts via 786	
bacteriophages, avoiding synthetic reactions. The encoded staple sequences were 787	
enzymatically synthetized as they were cut by two lateral Zn2+-dependent DNAzymes, 788	
thereby allowing biological production of both staples and scaffold245. In another route, staple 789	
strands were made by a new design and folding programme in order to exploit the self-790	
folding of single DNA or RNA strands into complex yet unknotted structures46. Both 791	
approaches will help deliver applications of nucleic acid nanostructures in, for example, 792	
therapy or intracellular reorganization of biological components11,1418. Biomedical and 793	
therapeutic applications can further exploit strategies to make DNA nanostructures 794	
compatible with the immune system of higher organisms246 and a fundamental 795	
understanding of the cellular uptake and processing of DNA nanostructures247 as well as 796	
their designed function inside cells56. As further advantage, nucleic acid structures can help 797	
advance biomedical applications with programmable intracellular biocomputation for 798	
triggered delivery of therapeutic cargo to target cells55. DNA nanotechnology can also be 799	
used for biosensing24861. Other areas of growth include the development of computational 800	
tools to guide and enhance the folding accuracy of DNA origami 249, or to increase the 801	
stability of DNA strands towards nucleases for biological or therapeutic applications18. 802	
 803	
Hybrid nanostructures composed of proteins and nucleic acids are also of considerable 804	
interest250, as the combined strength of the two components can compensate their isolated 805	
weaknesses. This is well illustrated by the ribosome, which is composed of RNA and 806	
polypeptides strands (Figure 6A). However, simpler hybrid systems have been engineered. 807	
For example, DNA scaffold have been used to arrange multiple enzymes or cofactors in a  808	
nanostructures enhancing the catalytic turn-over251, like biological catalytic cascades in 809	
confined environments122,123. Similar benefits were obtained for a DNA nanocage that 810	
encloses enzymes (Figure 6B)252,253, or a DNA nanorod that link two enzymes and an 811	
artificial swinging arm to channel substrates between the enzymes254. Furthermore, the 812	
activity of an enzyme was controlled by tethering it into a closable DNA vault. The unit could 813	
be opened by a DNA key and thereby allow the enzyme to regain steric access to the 814	
chemical substrates and restore catalytic activity255. However, structurally more less ordered 815	
assemblies can also result in catalytic enhancement as shown by linking enzymes to 816	
intracellular flexible RNA assemblies256. Hybrid nanostructures are also excellent tools in cell 817	
biological research. For example, DNA scaffolds can be used to expose activating protein-818	
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ligands to cells in well-defined arrangements, with full control over protein number, 819	
stoichiometry, and nanoscale distance257. DNA nanostructures are also templates to study 820	
movement of molecular motors53. Hybrids protein-DNA scaffolds of new defined geometry258 821	
can be created by stabilizing selected vertices of a DNA tetrahedron with duplex-binding 822	
RecA protein259. Furthermore, new function can also be enabled by puncturing lipid bilayer 823	
with hybrid pores to facilitate transport of large molecular cargo between the membrane 824	
barrier (Figure 6C). In these hybrids, a ring-shaped DNA scaffold arranges multiple tethered 825	
membrane-spanning peptide subunits into a contiguous pore of unusually large nanoscale 826	
diameter260.  827	
 828	
In conclusion, this Review has described how the different properties of proteins and nucleic 829	
acids define their engineering, function and suitability for specific applications. Although the 830	
building materials are different, there is considerable scope for working together and 831	
synergistically combining their strengths.  832	
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Box 1:  833	
Comparison of polypeptides’ and nucleic acids’ chemistry and structure 834	
 835	
Protein 
 
DNA/RNA 
Monomers and chemical properties 
 
The side chains of the 21 proteinogenic 
amino acids are structurally and chemically 
diverse. They cover a 2.8-fold size range 
(van der Waals volumes: 28 Å3, alanine; 79 
Å3, tryptophan)261 and a large chemical 
spectrum from aliphatic, aromatic, and polar 
to acidic and basic as shown in Figure 1. 
 
 
 
The four Watson–Crick bases are very 
similar in their flat aromatic structure. They 
cover a 1.4-fold size range (volumes: 66 
Å3, thymine; 93 Å3, guanine. Only the 
number and position of exocyclic 
substituents changes but there is no 
switch from apolar to polar, or negative to 
positive charges.  
 
Structural motives of polypeptides and nucleic acids 
 
The α-helix is stabilized by intra-backbone 
hydrogen bonding between N-H and C=O 
groups spaced by three residues. An α-
helical turn is completed by 3.6 residues with 
a rise of 0.15 nm per residue along the 
helical axis, and an advance per turn of 0.54 
nm. 
 
The β-sheet is formed by extended strands 
that interact via inter-backbone H-bonding. 
The strands are either parallel aligned with 
the N-termini at the same side, or antiparallel 
strands. Two residues complete a turn, the 
rise per residue is approx. 0.6 nm, and the 
distance between two strands is 0.5 nm.  
 
Coiled-coils are formed by two to up to seven  
α-helices stabilized by hydrophobic 
interactions. The helices feature heptead 
repeats with aliphatic amino acids in the 
position 1 and 4, and charged residues in 
positions 5 and 7. 
  
Polypeptide chains alter direction with turns 
that are named with a Greek letter to indicate 
the number of bonds: 5 to 1; π, α, β, γ, δ-
turns. 
 
The most prominent secondary structure 
for DNA is the B-type duplex and is 
stabilized by pairing between 
complementary bases. It has a diameter 
of 2 nm, 10.4 bp/turn, and a pitch of ~1.04 
nm. The persistence length for the DNA 
duplex is approx. 50 nm28 which is around 
50 times higher than for ssDNA.  
Hairpin, triplex, and quadruplex9,262,263 are 
other important secondary structures.  
 
Holliday junctions resemble a cross with 
four double stranded DNA arms and are 
relevant in DNA nanotechnology. The 
related double cross-over (DX) motif14 is 
widely used in DNA origami structures. It 
consists of two helical domains linked at 
two cross-over points that are similar to 
Holliday junctions. Other motives used in 
DNA nanotechnology are parameic 
crossover (PX) and JX2 motives14. 
 
 
  836	
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Box 2:  837	
Comparison of polypeptides’ and nucleic acids’ engineering and synthesis approaches 838	
 
Protein 
 
 
DNA/RNA 
Engineering and design approaches 
 
Directed evolution:  
The directed evolution involves the 
generation of a large library of randomized 
mutants of a gene with known corresponding 
protein structure. The  library members are 
expressed in cells1 or small cell-like 
vesicles264,265, via ribosome-display266, mRNA 
display32,33, or with phage-particles267 or 
yeast cells34-36 displaying the selectable 
proteins. Small libraries of peptide-like 
oligomers can be obtained via DNA-
templated synthesis137. Screening is 
performed to identify variants with the 
desired functional property29,31,268,269, and are 
usually followed by the amplification of the hit 
mutant genes. The process is often iterated. 
 
Rational design approaches:  
 
Rational engineering and computer-aided 
design are best conducted with a high-
resolution structure of the protein scaffold 
that helps to select those amino acids 
residues, peptide stretches, or even larger 
units that should be altered via site-directed 
mutagenesis. 
 
De novo protein design covers a wide range 
of approaches37-40,270. Its purest and most 
challenging form involves ab initio 
calculations to explore the full protein 
sequence space for a chosen architecture or 
function. Suitable structures and sequences 
are computationally screened by iteratively 
sampling the side chains (via the rotamers of 
all amino acids) and checking the structural 
validity of the backbone38. Some methods 
utilize as constraints secondary structure and 
contact predictions. Results can be cross-
checked by comparison with approaches that 
predict structures from known sequences38. 
 
Template-based methods begin with a 
sequence, predict the secondary structure, 
and attempt to find a template structure 
and/or fragments from existing scaffolds in 
  
Directed evolution: 
SELEX technology (systematic evolution 
of ligands by exponential 
enrichment)19,20,24 screens a RNA or DNA 
oligonucleotide library of randomized 
sequences to isolate binders to a target 
ligand, followed by polymerase chain 
reaction (PCR) amplification, and more 
cycles of screening and amplification.  
 
Rational design approaches: 
Tile assembly 179-182: Tiles composed of a 
few hybridized DNA oligonucleotides 
assemble into a regular array.  
 
Classical DNA origami10,184: A set of single 
stranded DNA oligonucleotides act as 
staples to direct the folding of a long 
ssDNA scaffold strand into a 
nanostructure with a single10 or multiple 
duplex layers184,185 arranged in square or 
honeycomb lattice. Design software 
caDNAno186 predict the sequences of 
staple strands  from a user-defined 
nanoshape of given geometry and 
dimensions. 
 
Curved DNA189,190: Within DNA origamis 
bases are inserted or deleted to uniformly 
twist or bend packs of duplexes189. 
Alternatively, DNA origamis with different 
curvatures in neighbouring duplexes are 
designed due to variable distances 
between cross-overs190. 
 
Brick-design197,198: Short oligonucleotides 
‘DNA bricks’, assemble into 3D structures 
without a long scaffold strand. The design 
units are cubes, which represents an 8 bp 
interaction between neighbouring strands.  
 
Wireframes187,194-196: Straight duplex 
modules are connected at tuneable angles 
into a network whereby the sides are not 
filled with DNA, unlike classical DNA 
	 19 
the protein data bank that will fold similar to 
the target sequence41.  
 
Folding of the polypeptide into the defined 
architecture can be an issue due to the 
complexity of the folding pathways but can 
be engineered271 with protein folding in vivo 
as [Au:OK?OK] a correction mechanism272. 
 
 
origami. 
 
Shape-complementarity192: DNA origamis 
assemble into larger units by shape-
complementarity with duplex protrusions 
fitting into the designed recession, 
independent of pairing. 
 
 
Synthetic approaches and chemical modifications 
 
Synthetic peptides of up to 50 residue can be 
generated via solid-phase peptide 
synthesis273. One or more synthetic 
fragments can be coupled via native 
chemical ligation238 or linked to biologically 
generated proteins via expressed protein 
ligation237 but also via Staudinger ligation273. 
 
Biologically generated proteins can be 
selectively chemically modified240 also by 
carrying out directed evolution with unnatural 
amino acids29. 
 
 
 
Solid-phase DNA oligonucleotide 
synthesis274 can yield up to 200 nt-long 
strands. Longer genes are assembled 
from partly overlapping 
oligonucleotides275,276 via PCR. 
 
Base and backbone modifications, 
generally summarized as xeno nucleic 
acid (XNA) can include backbone 
analogues peptide nucleic acid, 1,5-
anhydrohexitol nucleic acid, cyclohexene 
nucleic acid, glycol nucleic acid, locked 
nucleic acid, and threose nucleic acid. 
These and nucleobase analogues can be 
generated using chemical 
synthesis132,134,244,277 and optionally 
incorporated via enzyme-mediated 
polymerisation132,244 including an 
expanded genetic code239. Chemically 
modified DNA strands can also be 
obtained via DNA-templated synthesis to 
pre-arrange and ligate sequence-defined 
“codons” carrying chemically diverse side 
chains; and in vitro selection system 
screen for functional hybrid polymers that 
can be identified via DNA sequencing278.   
. 
 
 839	
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 841	
 842	
 843	
Figure 1 844	
Proteins and DNA/RNA. Structures of amino acids and polypeptide secondary structures 845	
(left column), and nucleotides and nucleic acid secondary structures (right column). Amino 846	
acid with 20 naturally occurring side chains (middle left) grouped according to similar 847	
chemical properties. Polypeptides’ secondary structures ɑ-helix, β-sheet and coiled coil 848	
(bottom left, side and helix view, polypeptides shown in red, and backbone represented as a 849	
grey ribbon). DNA nucleotides with the 4 naturally occurring DNA bases (top right). The 4 850	
bases interact via hydrogen bonding to yield Watson-Crick base pairs G-C and A-T (middle 851	
right). Anti-parallel DNA duplexes, A-, B and Z-forms, and other structures including hairpin 852	
junctions, triplexes and G-quadruplex (bottom right, DNA bases shown in red, and 853	
phosphodiester backbone represented as a grey ribbon). Scale bars, 1 nm. 854	
  855	
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 856	
 857	
Figure 2 858	
Natural and engineered proteins, and DNA nanostructures used for biomolecular 859	
recognition. (A) Antibody immunoglobin G structure as illustrated with a schematic drawing 860	
(bottom) and molecular model shown with a red ribbon (top). One light and half of one of the 861	
two heavy chains form one fragment antibody binding (Fab) region. The Fab also features 862	
the antigen-binding loops (ABL) which bind the antigen (grey). Two  halves of the heavy 863	
chain form the fragment crystallisable (Fc) region279. The inset shows the recognition of the 864	
HIV envelope glycoprotein (left) with an antigen binding loop (right)280. (B) A designed 865	
ankyrin repeat protein (DARPin, red/blue ribbon) interacting with signal transduction Ras 866	
GDP protein variant G12V (grey) that is involved in cancer development281. DARPin repeats 867	
have a structural motif of helix-turn-helix-β-hairpin. (C) A DNA aptamer inhibitor(red/blue) for 868	
lysophospholipase D Autotaxin (grey) which is a protein factor involved in cancer cell motility 869	
but also the adhesion of lymphocytes to immune organs282.  870	
  871	
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 872	
 873	
Figure 3 874	
Engineered bio-catalysts. (A) Enzyme retro-aldolase variant RA-61 (top) whose active site 875	
(green position in top, details see bottom) has been optimized with computer-based design 876	
including quantum mechanics and in vitro evolution and features lysine residues that interact 877	
with the substrate109. (B) Structure of the Kemp eliminase enzyme variant HG3.17 (top) with 878	
substrate 6-nitrobenzotriazole (green) bound in the active site shown in greater details at the 879	
bottom120. (C) Structure of a de novo designed enzyme (top) with a hydrolytically active 880	
catalytic triade Glu–His–Cys (position in green, detail at the bottom) embedded within the 881	
lumen of the α–helical bundle126. (D) Structure of the in vitro evolved ribozyme 9DB1 with 882	
ligase activity (top, active site green) with tertiary contacts within the catalytic domain 883	
(bottom)126. 884	
 885	
 886	
 887	
 888	
 889	
Figure 4 890	
Natural and engineered proteins that fulfil structural and cytoskeletal roles. (A) SbsB 891	
S-layer structure and lattice144. The image of the bacterium was rendered following ref283. (B) 892	
M13 bacteriophage filament (grey) composed of p8 subunit (red/blue ribbon)284. (C) BAR 893	
domain (red ribbon subunit), and rendering illustrating their binding to a curved membrane 894	
(grey)151. (D) A synthetic protein cage with subunit shown as red/blue ribbon (top) and as 895	
space-filling model (grey, with subunit shown in red/blue)162.   896	
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 897	
 898	
Figure 5 899	
Rationally designed DNA nanostructures. (A) A smiley face made by DNA origami10. The 900	
inset shows a Holliday junction where the scaffold strand is grey and the staple strands are 901	
colored. (B) Open and closed DNA origami box183. (C) Clathrin-triskelion-like DNA origami 902	
nanostructures (subunit red/blue) assemble via adhesion on a supported lipid bilayer 903	
membrane into a regular array (grey)191. (D) DNA robots with closed and open arms (blue 904	
shades show the shape-complementary-based interactions)192. The open and closing is 905	
induced by modulating the electrostatic repulsion via the salt concentration. (E) 906	
Reconfigurable DNA nanocages (top, blue) assemble to complete a ring-like exoskeleton 907	
(grey) that templates a circular lipid tube (green)199.  908	
 909	
 910	
 911	
 912	
 913	
 914	
 915	
Figure 6  916	
Natural and engineered hybrid systems that combine proteins and DNA/RNA. (A) 917	
Ribosome composed of RNA and polypeptide strands285. (B) Nanocaged enzymes with 918	
enhanced catalytic activity and increased stability against protease digestion253. (C) Hybrid 919	
nanopores constructs with the ring-like DNA domain (red) and membrane-spanning peptide 920	
domain (blue)260. 921	
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